BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pittet LF, Posfay-Barbe KM. Vaccination of immune compromised children-an overview for physicians. Eur J Pediatr 2021;180:2035-47. [PMID: 33665677 DOI: 10.1007/s00431-021-03997-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Garrido-Jareño M, Sahuquillo-Arce JM, Rodríguez-Vega H, Lloret-Sos C, Gil-Brusola A, López-Hontangas JL, Nuñez-Beltran M, Tortosa-Carreres J, García-García JÁ, Cordón L, Puchades-Carrasco L, de Santivañes CC, Pineda-Lucena A, Pemán-García J. IgG antibody response to pneumococcal-conjugated vaccine (Prevenar®13) in children with immunodeficiency disorders. Med Microbiol Immunol 2023;212:93-102. [PMID: 36595027 DOI: 10.1007/s00430-022-00759-0] [Reference Citation Analysis]
2 Watson C, Davies B, Camara C. A brief guide to immunisation and the immunocompromised child or young person. Practice Nursing 2023;34:28-32. [DOI: 10.12968/pnur.2023.34.1.28] [Reference Citation Analysis]
3 Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Osteosarcoma. Nat Rev Dis Primers 2022;8:77. [PMID: 36481668 DOI: 10.1038/s41572-022-00409-y] [Reference Citation Analysis]
4 Watson C, Davies B, Camara C. A brief guide to immunisation and the immunocompromised child or young person. Br J Nurs 2022;31:1029-1032. [DOI: 10.12968/bjon.2022.31.20.1029] [Reference Citation Analysis]
5 Blanchard-rohner G, Pittet LF. Discussion. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-04844-9_7] [Reference Citation Analysis]
6 Blanchard-rohner G, Pittet LF. Vaccination Schedules in Immunocompromised Children. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-04844-9_5] [Reference Citation Analysis]
7 Blanchard-rohner G, Pittet LF. Importance of Vaccinating Immunocompromised Children. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-04844-9_1] [Reference Citation Analysis]
8 Hecker-Nolting S, Langer T, Blattmann C, Kager L, Bielack SS. Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients. Cancer Manag Res 2021;13:8989-98. [PMID: 34880679 DOI: 10.2147/CMAR.S287908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Landier W, Bhatia S, Wong FL, York JM, Flynn JS, Henneberg HM, Singh P, Adams K, Wasilewski-Masker K, Cherven B, Jasty-Rao R, Leonard M, Connelly JA, Armenian SH, Robison LL, Giuliano AR, Hudson MM, Klosky JL. Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial. Lancet Child Adolesc Health 2022;6:38-48. [PMID: 34767765 DOI: 10.1016/S2352-4642(21)00278-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Beni A, Mazzilli S, Bellino E, Costagliola G, Ferretti E, Lopalco PL, Tavoschi L, Peroni DG. Uptake of Vaccinations among Children with Chronic Diseases Is Affected by Knowledge Gaps and Implementation Challenges in Italy. Vaccines (Basel) 2021;9:1217. [PMID: 34835148 DOI: 10.3390/vaccines9111217] [Reference Citation Analysis]